20 Aug Sanochemia Pharmazeutika, Vienna, acquires majority shares of AlcaSynn Pharmaceuticals, for 12 mn EURO
Left to right: AlcaSynn CEO Peter Kayatz, Sonja Hammerschmid, authorized officer of the Austrian Business Development Bank (AWS), Herwig van Staa, Governor of the Federal State of Tyrol, Josef Boeckmann, CEO of Sanochemia, and Professor Manfried Gantner, Dean of Innsbruck University, are announcing the corporate deal at the annual European Forum Alpbach, 2006.
Product and Partners
AS006, the lead compound of AlcaSynn, is a peripherally acting mu-opioid agonist, designed for the treatment of severe pain, with markedly reduced centrally mediated side effects, e.g. dizziness or hallucinations.
AlcaSynn Pharmaceuticals GmbH, Innbruck, Austria, is spin-off from the University of Innsbruck, and focusses on the development of morphinan drugs, that have the potential to be developed for a multitude of different clinical indications, e.g. pain, inflammation, diarrhea, or parkinson’s disease. AlcaSynn disposes of a patent portfolio of 15 granted patents and another 24 patents filed.
The group of Professor Schmidhammer is one of the leading academic groups in the field of morphinan chemistry.
Peter joint AlcaSynn as interim manager in 2003, before taking over responsibility as CEO of AlcaSynn in 2004.
Sanochemia Pharmazeutika AG, Vienna, Austria, is a specialty pharmaceuticals company with its own production facilities and developmental expertise. Sanochemia focusses on the indication areas of neurodegeneration, pain, oncology and clinical diagnostics.
- Interim manager of AlcaSynn from 2003 to 2004 until the incorporation as a GmbH (Ltd.).
- CEO of AlcaSynn since incorporation in 2004.
- Setup of organization.
- Acquisition of grants and soft Loans > 1 Mio. €.
- Acquisition of corporate venture capital > 10 Mio. €.
- Trade Sale to Sanochemia Pharmazeutika, Vienna, in 2006. Pre-money valuation of 8 mn €.